Page 98 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

The addition of neoadjuvant and adjuvant pembrolizumab to standard chemotherapy and surgery may improve outcomes in patients with early-stage non-small cell lung cancer

1. At 24 months, more participants in the pembrolizumab group were alive without an event, compared with the placebo group. 2. 24-month survival in the pembrolizumab group was 80.9% as compared to 77.6% of placebo group patients. Evidence Rating Level: 1 (Excellent) Study Rundown: Standard treatments for advanced non-small-cell lung cancer (NSCLC) includes programmed cell ....

Minute Medicine Inc , Rating Level , Non Small Cell Lung Cancer Nsclc , Peri Operative Immunotherapy , Chronic Disease ,

Senate bill includes funds for YRMC radiation therapy equipment

A proposed U.S. Senate bill includes funding for radiation therapy equipment for the Yuma Regional Medical Center Cancer Center. If approved, the total award for YRMC would be $1.5 million. ....

United States , Kyrsten Sinema , Abhinavb Chandra , Mark Kelly , Robert Trenchel , Senate On , Human Services , House Appropriations Committee , Yuma Regional Medical Center Cancer , Cancer Center , Us Senate , Education Appropriations Act , Varian Truebeam , He Economy , Health Care , Tomic Physics ,

YMCA group fosters community for cancer patients

A YMCA program that provides a space for cancer patients to work on both physical and mental health is continuing to make an impact in the community as the group ....

Jeff Penland , Linda Mcneiley ,

Damascus event has now raised $1.25M for cancer reserach

A long-time, local cancer fundraising effort established a new single-year record last month when the Creeper Trail Ride to End Cancer donated $100,000 to University of Texas M.D. Anderson Cancer ....

United States , Robert Benjamin , National Cancer Institute , Creeper Trail Ride , End Cancer , Penny Garrett , Olivia French , Creeper Trail ,

Talazoparib plus enzalutamide improves progression-free survival in metastatic prostate cancer

1. Progression-free survival was significantly higher in the talazoparib plus enzalutamide group compared to enzalutamide alone. 2. There were no treatment-related fatalities among patients in the talazoparib group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer is the second most common malignancy among men. Despite existing therapies, metastatic castration-resistant prostate cancer (mCRPC) remains a ....

Rating Level , Metastatic Castration Resistant Prostate , Between Jan , Metastatic Castration Resistant Prostate Cancer , Metastatic Castration Resistant Prostate Cancer Mcrpc , Prostate Cancer , Prostate Cancer Metastasis , Chronic Disease ,